Recent development in the field of dual COX / 5-LOX inhibitors.
Cyclooxygenases and lipoxygenase are key enzymes in the arachidonic acid metabolism. Dual inhibitors are drugs able to block both the COX and the 5-LOX metabolic pathways. Compared to COX or LOX pathways single inhibitors, dual inhibitors present at least two major advantages. First, dual inhibitors, by acting on the two major arachidonic acid metabolic pathways, possess a wide range of anti-inflammatory activities. Secondly, dual inhibitors appear to be almost exempt from gastric toxicity, which is the most troublesome side effect of non-selective COX inhibitors.
Natural and Synthetic Drugs Research Center, Department of Medicinal Chemistry, Université de Liège, 1 av. de l'Hôpital, tour 4(+5) Sart-Tilman, B-4000 Liège, Belgium. f.julemont@ulg.ac.be
Fabien
F
Julémont
Jean-Michel
JM
Dogné
Bernard
B
Pirotte
Xavier
X
de Leval
D016718:Arachidonic Acid / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D008084:Lipoxygenase / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D015398:Signal Transduction; D013449:Sulfonamides / Q000737:chemistry / Q000494:pharmacology
D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D013449:Sulfonamides; D016718:Arachidonic Acid; D008084:Lipoxygenase; D011451:Prostaglandin-Endoperoxide Synthases